SDC4 (Ab-179) Antibody

What is the specificity of SDC4 (Ab-179) Antibody?

SDC4 (Ab-179) Antibody is a polyclonal antibody that specifically targets Syndecan 4 around the phosphorylation site of serine 179 (E-G-S(p)-Y-D) in the protein sequence. The antibody detects endogenous levels of total Syndecan 4 (SDC4) protein . It was produced using a synthesized non-phosphopeptide derived from human Syndecan 4 as the immunogen. The specificity of this antibody allows researchers to examine the presence and levels of SDC4 protein in various experimental contexts, particularly when investigating cellular signaling pathways involving this proteoglycan. When designing experiments, researchers should note that the antibody cross-reacts with human, mouse, and rat samples, making it versatile for comparative studies across these species .

What applications is SDC4 (Ab-179) Antibody validated for?

The SDC4 (Ab-179) Antibody has been validated for multiple applications, providing researchers with flexibility in experimental design. The primary applications include:

• Western Blotting (WB): Recommended dilution ranges from 1/500 to 1/3000

• Immunohistochemistry (IHC): Recommended dilution ranges from 1/50 to 1/100

• Immunofluorescence (IF)/Immunocytochemistry (ICC): Recommended dilution ranges from 1/100 to 1/500

• ELISA: Recommended dilution is approximately 1/40000

When selecting this antibody for a specific application, researchers should consider performing preliminary dilution tests to determine the optimal concentration for their specific experimental conditions. The antibody's affinity purification from rabbit antiserum using epitope-specific immunogen enhances its specificity across these applications .

How should SDC4 (Ab-179) Antibody be stored and handled to maintain its efficacy?

For optimal performance and longevity, researchers should store SDC4 (Ab-179) Antibody in aliquots at -20°C and avoid repeated freeze/thaw cycles . The antibody is typically supplied in liquid form in a buffer consisting of PBS (without Mg²⁺ and Ca²⁺), pH 7.4, containing 150 mM NaCl, 0.02% sodium azide, and 50% glycerol . When planning experiments, consider preparing working aliquots to prevent protein degradation from multiple freeze-thaw events. Proper storage and handling practices are crucial for maintaining antibody specificity and sensitivity, directly impacting experimental outcomes. Before use, allow the antibody to equilibrate to room temperature gradually and mix gently to ensure homogeneity without introducing bubbles that might interfere with pipetting accuracy.

How can SDC4 (Ab-179) Antibody be used to investigate the role of SDC4 in inflammatory processes?

Recent research has highlighted the significant role of SDC4 in inflammatory processes, particularly in LPS-induced sepsis-associated acute lung injury (ALI) . When designing experiments to investigate this relationship, researchers can use SDC4 (Ab-179) Antibody in combination with inflammatory markers.

Bioinformatics analysis has shown that SDC4 expression is upregulated approximately 4.5-fold in response to LPS stimulation, while SDC2 remains relatively stable . This differential expression pattern suggests that SDC4 plays a specific role in inflammatory responses. Experimental approaches might include:

• Western blotting with SDC4 (Ab-179) Antibody to quantify SDC4 expression levels in control versus LPS-treated samples

• Immunofluorescence to visualize the cellular localization of SDC4 during inflammatory responses

• Co-immunoprecipitation studies to investigate interactions between SDC4 and inflammatory mediators such as CCL5, CXCL8, CXCL10, and IL-1B

For comprehensive analysis, researchers can correlate SDC4 expression levels with the expression of key inflammatory cytokines (IL-6, IL-1β, and VCAM-1), which have been shown to increase following SDC4 knockdown .

What are the potential limitations when using SDC4 (Ab-179) Antibody in tissue-specific studies?

While SDC4 (Ab-179) Antibody provides valuable insights into SDC4 expression and function, researchers should be aware of potential limitations when conducting tissue-specific studies:

• Expression level variations: SDC4 expression levels differ significantly across tissues and cell types. For instance, SDC1 and SDC3 typically show mean expression levels of 5-6, while SDC2 and SDC4 are expressed at 500-1500 times higher levels in certain contexts .

• Temporal expression patterns: Consider the dynamic nature of SDC4 expression during inflammatory responses. Research indicates that peak SDC4 expression might occur at relatively early phases (around 6 hours post-stimulation), while peak inflammatory states might manifest later (24 hours post-LPS induction) .

• Cross-reactivity considerations: Although the antibody is validated for human, mouse, and rat samples, subtle species-specific differences in epitope structure might affect binding affinity and specificity. Validation using appropriate positive and negative controls is recommended when studying novel tissue types.

• Post-translational modifications: The phosphorylation status of Ser179 might vary depending on cellular context and signaling conditions, potentially affecting antibody recognition.

When conducting tissue-specific studies, researchers should consider these limitations and implement appropriate controls to validate findings.

How can SDC4 (Ab-179) Antibody be integrated into studies investigating SDC4's role in signaling pathways?

Integrating SDC4 (Ab-179) Antibody into signaling pathway studies requires careful experimental design. Evidence suggests that SDC4 is regulated by nuclear factor kappa beta (NF-κβ) and plays a role in mediating inflammatory responses . To investigate these relationships:

• Dual immunolabeling approaches: Combine SDC4 (Ab-179) Antibody with antibodies against known signaling mediators (like NF-κβ components) for co-localization studies using confocal microscopy.

• Temporal analysis: Design time-course experiments to track SDC4 expression and phosphorylation status following stimulation with inflammatory mediators. SDC4 (Ab-179) Antibody can be used in parallel with phospho-specific antibodies to distinguish between total and phosphorylated forms.

• Pathway inhibition studies: Use specific inhibitors of the NF-κβ pathway in combination with SDC4 (Ab-179) Antibody detection to establish regulatory relationships. For example, examining how NF-κβ inhibition affects SDC4 expression levels.

• SDC4 knockdown/knockout models: Compare antibody staining patterns in wild-type versus SDC4-depleted systems to validate specificity and investigate downstream effects on inflammatory signaling networks.

These approaches can help elucidate SDC4's position within cellular signaling networks and its functional implications in inflammatory processes.

What controls should be included when using SDC4 (Ab-179) Antibody in experimental procedures?

Implementing appropriate controls is crucial for ensuring the validity and reliability of experiments using SDC4 (Ab-179) Antibody:

• Positive controls: Include samples known to express SDC4 at detectable levels. For human samples, endothelial cells stimulated with LPS have demonstrated significant SDC4 expression .

• Negative controls: Use samples from SDC4 knockdown experiments or tissues known to have minimal SDC4 expression. Alternatively, include a control using only secondary antibody (without primary antibody) to assess non-specific binding.

• Isotype controls: Include a non-specific rabbit IgG at equivalent concentrations to the SDC4 (Ab-179) Antibody to identify any potential non-specific binding.

• Peptide competition assays: Pre-incubate the antibody with excess immunizing peptide to block specific binding sites and confirm signal specificity.

• Cross-reactivity controls: If studying a specific species, include samples from other species to validate the cross-reactivity claims, especially when working with less commonly studied organisms.

These controls help distinguish between specific signals and background noise, enhancing the reliability of experimental findings and facilitating accurate interpretation of results.

How can optimal dilution of SDC4 (Ab-179) Antibody be determined for different experimental applications?

Determining the optimal dilution of SDC4 (Ab-179) Antibody requires a systematic approach tailored to each application:

For Western blotting optimization:

• Load equal amounts of protein across multiple lanes

• Test a range of antibody dilutions (e.g., 1/500, 1/1000, 1/2000, 1/3000)

• Evaluate band intensity, background signal, and specificity

• Select the dilution that provides optimal signal-to-noise ratio while conserving antibody

For microscopy applications (IHC/IF):

• Use positive control samples with known SDC4 expression

• Test multiple dilutions on serial sections

• Evaluate staining intensity, background, and subcellular localization patterns

• Consider counterstaining to assess tissue morphology and provide context

Remember that optimal dilutions may vary depending on sample type, protein expression levels, and detection methods. Document optimization procedures for reproducibility in future experiments.

What techniques can be used to validate the specificity of SDC4 (Ab-179) Antibody in experimental systems?

Validating the specificity of SDC4 (Ab-179) Antibody is essential for ensuring reliable experimental results. Several complementary approaches can be employed:

• SDC4 knockdown/knockout validation: Compare antibody staining patterns between wild-type samples and those with reduced or eliminated SDC4 expression. A specific antibody should show significantly reduced or absent signal in knockdown/knockout samples.

• Mass spectrometry validation: Following immunoprecipitation with SDC4 (Ab-179) Antibody, subject the precipitated proteins to mass spectrometry analysis to confirm the presence of SDC4 and assess any non-specific interactions.

• Multiple antibody comparison: Use alternative SDC4 antibodies targeting different epitopes and compare staining patterns. Concordant results across different antibodies increase confidence in specificity.

• Recombinant protein controls: Test the antibody against purified recombinant SDC4 protein versus other syndecan family members (SDC1, SDC2, SDC3) to assess cross-reactivity within the protein family.

• Epitope mapping: If resources allow, conduct epitope mapping experiments to precisely define the binding region and confirm recognition of the Ser179 region.

• Western blot molecular weight verification: Confirm that the detected protein band matches the expected molecular weight of SDC4 (~20-22 kDa core protein, though apparent MW may be higher due to glycosylation).

Implementing these validation strategies provides robust evidence for antibody specificity and strengthens the credibility of experimental findings.

How should researchers interpret variations in SDC4 detection patterns across different cell types and tissues?

Interpreting variations in SDC4 detection patterns requires consideration of multiple biological and technical factors:

• Baseline expression differences: Research indicates substantial variance in baseline SDC4 expression across tissues. For instance, SDC2 and SDC4 expression can be 500-1500 times higher than SDC1 and SDC3 in certain contexts . When comparing SDC4 levels between different cell types, normalize data appropriately and consider these inherent differences.

• Post-translational modifications: SDC4 undergoes various post-translational modifications, including glycosylation and phosphorylation, which may affect antibody recognition. Different cell types might process SDC4 differently, resulting in altered detection patterns despite similar expression levels.

• Functional contexts: The physiological role of SDC4 may vary across tissues. In lung microvascular endothelial cells, SDC4 plays a protective role in LPS-induced inflammation , but its function might differ in other contexts. Interpret detection patterns within the appropriate functional framework.

• Subcellular localization: SDC4 can be membrane-bound or present in soluble form following shedding. The relative distribution between these forms may vary by cell type and physiological state, affecting detection patterns.

• Temporal dynamics: Consider time-dependent expression changes, particularly in response to stimuli. Peak SDC4 expression in inflammatory responses may occur at specific time points (e.g., 6 hours post-LPS induction), with different kinetics across cell types .

To accurately interpret these variations, combine SDC4 (Ab-179) Antibody staining with complementary techniques such as mRNA quantification, and contextualize findings within the specific biological system under investigation.

What are the implications of SDC4 phosphorylation at Ser179 for interpreting antibody detection results?

The SDC4 (Ab-179) Antibody targets the region around serine 179, making it important to consider the phosphorylation status of this residue when interpreting results:

• Phosphorylation-dependent epitope masking: Although the antibody was raised against a non-phosphopeptide derived from human Syndecan 4 around the phosphorylation site , the phosphorylation state of Ser179 in experimental samples might affect antibody binding. Researchers should consider whether their experimental conditions might induce phosphorylation changes at this site.

• Signaling pathway context: Ser179 phosphorylation is likely regulated by specific kinases and phosphatases in response to cellular signaling events. When interpreting SDC4 detection patterns, consider the activation status of relevant signaling pathways, particularly those involving NF-κβ, which has been implicated in SDC4 regulation .

• Functional implications: Phosphorylation at Ser179 may alter SDC4's functional properties, including its interactions with other proteins or its role in inflammatory processes. Changes in detection patterns might reflect not only changes in expression levels but also post-translational modifications with functional significance.

• Complementary approaches: To fully interpret the significance of SDC4 detection patterns, consider using phospho-specific antibodies in parallel with SDC4 (Ab-179) Antibody to distinguish between total and phosphorylated forms of the protein.

Understanding these implications allows for more nuanced interpretation of experimental results and can provide insights into the functional state of SDC4 in different biological contexts.

How can researchers correlate SDC4 expression data with functional outcomes in inflammatory disease models?

Correlating SDC4 expression with functional outcomes in inflammatory disease models requires integrated analytical approaches:

• Temporal correlation analysis: Track SDC4 expression levels using SDC4 (Ab-179) Antibody alongside disease progression markers over time. In sepsis-associated acute lung injury models, SDC4 expression peaks relatively early (around 6 hours post-LPS induction), while inflammatory markers may peak later (around 24 hours) . This temporal relationship can provide insights into SDC4's role in disease pathogenesis.

• Loss-of-function approaches: Combine SDC4 knockdown or knockout with antibody-based expression analysis in remaining cells to assess functional consequences. Research has shown that SDC4 knockdown exacerbates inflammatory injury and increases expression of inflammatory cytokines (IL-6, IL-1β, and VCAM-1) , suggesting a protective role.

• Signaling pathway integration: Analyze SDC4 expression in relation to NF-κβ activation and other inflammatory signaling pathways. Evidence suggests that SDC4 is regulated by NF-κβ , making this relationship particularly important to investigate.

• Histopathological correlation: Correlate SDC4 immunostaining patterns with histopathological features of disease progression, such as inflammatory cell infiltration, tissue damage, and remodeling.

• Multi-marker analysis: Assess SDC4 expression alongside its associated molecules (CCL5, CXCL8, CXCL10, IL-1B) to create a more comprehensive picture of the inflammatory network.

This integrative approach can help establish whether SDC4 serves as a biomarker for disease progression, a therapeutic target, or both, and can guide the development of intervention strategies for inflammatory conditions.

What are potential solutions for weak or absent signal when using SDC4 (Ab-179) Antibody?

When faced with weak or absent signals using SDC4 (Ab-179) Antibody, consider the following troubleshooting approaches:

• Antibody concentration optimization: The recommended dilution ranges (WB: 1/500-1/3000; IHC: 1/50-1/100; IF/ICC: 1/100-1/500; ELISA: 1/40000) may need adjustment for specific samples. Try using a more concentrated antibody solution while monitoring background.

• Sample preparation improvements:

  • For Western blotting: Ensure sufficient protein loading (20-50 μg total protein), optimize extraction buffer to preserve SDC4, and consider using PVDF membranes which may provide better protein retention

  • For IHC/IF: Test different fixation methods, as overfixation can mask epitopes; try antigen retrieval techniques (heat-induced or enzymatic)

• Detection system enhancement: Switch to a more sensitive detection system, such as amplified chromogenic detection for IHC or tyramide signal amplification for IF/ICC.

• Epitope accessibility issues: If target epitopes are masked, try different antigen retrieval methods or alternative sample preparation techniques that might better expose the Ser179 region.

• Expression level verification: Confirm SDC4 expression in your samples using RT-PCR or other methods, as expression levels vary significantly across tissues and cell types .

• Antibody quality assessment: Check antibody storage conditions and age; consider obtaining a fresh lot if the current one has undergone multiple freeze-thaw cycles or is beyond its recommended shelf life.

Systematic testing of these variables can help identify and resolve issues leading to suboptimal signal detection.

How can researchers address non-specific binding or high background when using SDC4 (Ab-179) Antibody?

High background or non-specific binding can compromise experimental results. Here are strategies to mitigate these issues:

• Blocking optimization:

  • Test different blocking agents (BSA, normal serum, commercial blockers) at various concentrations

  • Extend blocking time (from typical 1 hour to 2-3 hours or overnight at 4°C)

  • Include blocking agents in antibody diluent solutions

• Antibody dilution adjustment: Test more dilute antibody solutions, as excessive antibody concentration can contribute to non-specific binding.

• Washing protocol enhancement:

  • Increase washing duration and frequency

  • Use higher stringency wash buffers (consider adding 0.1-0.5% Tween-20 or Triton X-100)

  • Implement temperature variations (cold or warm washing solutions)

• Secondary antibody optimization: Ensure secondary antibody is appropriate for the host species (rabbit) and is highly cross-adsorbed against potential cross-reactive species.

• Endogenous peroxidase/phosphatase quenching: For enzymatic detection systems, thoroughly quench endogenous enzymes that might contribute to background.

• Tissue/sample preparation refinement:

  • Minimize fixation-induced autofluorescence

  • Consider Sudan Black B treatment to reduce lipofuscin autofluorescence in certain tissues

  • Use freshly prepared samples when possible

• Negative control inclusion: Always run a negative control (omitting primary antibody) to assess the contribution of non-specific secondary antibody binding to background signal.

Implementing these strategies systematically can significantly improve signal-to-noise ratio and enhance the specificity of SDC4 detection.

What strategies can help researchers validate contradictory findings when using SDC4 (Ab-179) Antibody?

When faced with contradictory findings in SDC4 research, systematic validation approaches can help resolve discrepancies:

• Technical replication with methodological variations:

  • Test different sample preparation methods

  • Use alternative detection systems

  • Vary experimental conditions (temperature, incubation times, buffers)

  • Compare results across multiple experimental platforms (e.g., WB, IHC, IF)

• Biological validation using complementary techniques:

  • Correlate antibody-based protein detection with mRNA quantification (RT-PCR, RNA-seq)

  • Implement mass spectrometry-based protein identification

  • Use alternative SDC4 antibodies targeting different epitopes

  • Employ functional assays to corroborate expression data

• Genetic approaches:

  • Utilize SDC4 knockdown/knockout models as negative controls

  • Implement SDC4 overexpression systems as positive controls

  • Use CRISPR-Cas9 to modify the endogenous SDC4 gene and assess effects on antibody binding

• Context-dependent analysis:

  • Consider cell type-specific differences in SDC4 expression and processing

  • Assess temporal dynamics, as SDC4 expression patterns change over time in response to stimuli

  • Evaluate the influence of specific experimental conditions (e.g., LPS treatment, inflammatory stimuli)

• Literature-based reconciliation:

  • Compare findings with published SDC4 expression patterns

  • Consider species-specific differences that might explain discrepancies

  • Evaluate methodological differences between studies that might account for contradictory results

By implementing these validation strategies, researchers can resolve contradictions and develop a more accurate understanding of SDC4 biology in their specific experimental context.

How might SDC4 (Ab-179) Antibody contribute to understanding the protective role of SDC4 in acute lung injury?

Research has indicated that SDC4 plays a protective role in acute lung injury, with SDC4 knockdown exacerbating inflammatory damage . SDC4 (Ab-179) Antibody can contribute to advancing this research in several ways:

• Tracking SDC4 expression dynamics: Monitor the temporal and spatial patterns of SDC4 expression during the progression of acute lung injury using immunohistochemistry and immunofluorescence. This could help identify critical timepoints for potential therapeutic intervention.

• Cell-specific expression profiling: Combine SDC4 (Ab-179) Antibody with cell-type-specific markers in co-immunostaining experiments to determine which pulmonary cell populations express SDC4 during inflammation and how this expression changes with disease progression.

• Signaling pathway investigation: Use the antibody in conjunction with phospho-specific antibodies for NF-κβ pathway components to elucidate the bidirectional relationship between SDC4 and inflammatory signaling. This could clarify whether SDC4 acts upstream or downstream of key inflammatory mediators.

• Post-translational modification analysis: Investigate how phosphorylation at or near Ser179 affects SDC4's protective functions by correlating phosphorylation status with disease severity and inflammatory marker expression.

• Therapeutic monitoring: Evaluate the efficacy of potential therapeutic interventions targeting the SDC4 pathway by monitoring changes in SDC4 expression, localization, and phosphorylation in response to treatment.

These approaches could significantly enhance our understanding of SDC4's protective mechanisms and potentially inform the development of novel therapeutic strategies for acute lung injury and other inflammatory conditions.

What novel research applications might emerge for SDC4 (Ab-179) Antibody beyond current established uses?

The SDC4 (Ab-179) Antibody holds potential for several innovative research applications that extend beyond its conventional uses:

• Single-cell proteomics integration: Combine SDC4 (Ab-179) Antibody with single-cell analysis techniques to map SDC4 expression heterogeneity within tissues and correlate this with cellular phenotypes and functions at unprecedented resolution.

• Extracellular vesicle (EV) research: Investigate SDC4 incorporation into EVs and its potential role in intercellular communication during inflammatory responses, using the antibody for EV characterization and tracking.

• Live-cell imaging applications: Develop non-disruptive labeling strategies using SDC4 (Ab-179) Antibody fragments or derivatives to track SDC4 dynamics in living cells during inflammatory responses.

• Biomarker development: Explore the potential of SDC4 as a biomarker for inflammatory conditions, using the antibody in the development of diagnostic assays that could predict disease progression or treatment response.

• Drug discovery platforms: Incorporate the antibody into high-throughput screening systems to identify compounds that modulate SDC4 expression or phosphorylation, potentially leading to novel anti-inflammatory therapeutics.

• Regenerative medicine applications: Investigate SDC4's role in tissue repair and regeneration following inflammatory injury, using the antibody to track SDC4 expression during healing processes.

• Artificial intelligence integration: Combine SDC4 immunostaining with AI-based image analysis to identify subtle patterns in SDC4 expression and localization that correlate with disease states or outcomes.

These emerging applications could significantly expand the utility of SDC4 (Ab-179) Antibody in both basic research and translational medicine contexts.

How might methodological advances improve the utility of SDC4 (Ab-179) Antibody in complex research settings?

Emerging methodological advances could enhance the utility of SDC4 (Ab-179) Antibody in complex research settings:

• Multiplexed immunolabeling technologies: Integration with multiplexed immunofluorescence or mass cytometry (CyTOF) would allow simultaneous detection of SDC4 alongside numerous other markers, providing comprehensive insights into cellular phenotypes and signaling networks.

• Advanced tissue clearing techniques: Combining the antibody with tissue clearing methods (CLARITY, iDISCO, etc.) could enable three-dimensional visualization of SDC4 distribution across intact organs, revealing spatial relationships impossible to discern in traditional thin sections.

• In situ proximity ligation assays: Adaptation for proximity ligation would enable visualization of specific protein-protein interactions involving SDC4, providing functional insights beyond mere expression data.

• Super-resolution microscopy compatibility: Optimization for super-resolution techniques (STORM, PALM, STED) could reveal nanoscale organization of SDC4 at the cell membrane and in intracellular compartments.

• Microfluidic immunoassays: Integration with microfluidic platforms could enable real-time monitoring of SDC4 expression in response to various stimuli with minimal sample consumption.

• Antibody engineering: Development of recombinant antibody fragments or nanobodies targeting the same epitope could improve tissue penetration, reduce non-specific binding, and enhance compatibility with various imaging modalities.

• Computational image analysis pipelines: Creation of specialized algorithms for automated quantification of SDC4 expression patterns could standardize analysis across laboratories and enhance reproducibility.